Picture EBD Group World of Partnering Opportunities 650x100px
Document › Details

Evotec AG. (7/19/18). "Press Release: Evotec Receives Milestone Payment for Start of Phase II Trial in Its Multi-target Alliance with Bayer". Hamburg.

Organisations Organisation Evotec AG (FSE: EVT, TecDAX)
  Today Evotec SE (FSE: EVT, MDA X/TecDAX, Nasdaq: EVO)
  Group Evotec (Group)
  Organisation 2 Bayer AG
  Group Bayer (Group)
Products Product small-molecule drug
  Product 2 clinical research
Persons Person Lanthaler, Werner (Evotec AG 200903– CEO before Intercell AG CFO before Austrian Industrial Assoc before McKinsey)
  Person 2 Hansen, Gabriele (Evotec 201404 VP Corporate Communications + Investor Relations)

Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that its multi-target alliance with Bayer in the field of endometriosis has advanced a promising small molecule into Phase II clinical development for the treatment of chronic cough, resulting in a payment of EUR 4 m to Evotec.

Chronic cough is a major global health burden and has a significant impact on the quality of life of millions of people. Currently, no therapies are approved for the treatment of chronic cough.

This new trial has been initiated following positive results from a Phase I study which is part of the ongoing Bayer-Evotec endometriosis alliance. The potential to treat patients with a persistent chronic cough was highlighted due to the nature and expression of the target protein being originally explored for the treatment of endometriosis. The clinical Phase I trial in healthy volunteers started in 2017 and has now advanced into Phase II trial in chronic cough in July 2018.

The Evotec-Bayer multi-target discovery alliance was entered in October 2012. The goal of this collaboration is to discover three clinical candidates within the alliance. Both parties contribute innovative drug targets and high-quality technology infrastructures and share the responsibility for early research and pre-clinical characterisation of potential clinical candidates in the disease area of endometriosis. Since the beginning of the collaboration, six first-in-class non-hormonal pre-clinical candidates have been generated; three of those progressed into Phase I clinical trials in endometriosis and chronic cough.

Dr Werner Lanthaler, Chief Executive Officer of Evotec, commented: "Since we began collaborating with Bayer in 2012, the joint teams have combined cutting-edge science, significant drug discovery expertise, and a shared commitment to bring new therapeutics options to the millions of patients. With the advancement of our first novel drug candidate into Phase II studies we continue to grow and build out our strong partnered pipeline. We look forward to further advancing our target portfolio across a developing range of potential therapeutic indications, especially for patients with unexplained chronic cough new and effective treatment options are urgently needed."


Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, infectious diseases, diabetes and complications of diabetes, pain, inflammation, and oncology and. On this basis, Evotec has built a broad and deep pipeline of more than 80 partnered product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term discovery alliances with partners including Bayer, CHDI, Sanofi and UCB and development partnerships with e.g. Sanofi in the field of diabetes, Pfizer in the field of tissue fibrosis and Celgene in the field of neurodegenerative diseases. For additional information, please go to


Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

Contact Evotec AG:

Gabriele Hansen, VP Corporate Communications & Investor Relations, Phone: +49.(0)40.56081-255,

Record changed: 2023-06-05


Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

More documents for Evotec (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Berlin Partner Top News Bayer Aignostics Collaboration 650x300px

» top